Acute Decompensated Heart Failure
Abstract
Heart failure (HF) is a clinical syndrome marked by elevated filling pressures to maintain acceptable cardiac output. Current guidelines use left ventricular ejection fraction (LVEF) to distinguish between reduced (HFrEF; LVEF 50%) and midrange ejection fractions (HFmrEF; LVEF between 40–49%). Beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor neprilysin inhibitors (ARNI), sodium-glucose transporter-2 (SGLT2) inhibitors and cardiac resynchronization therapy, among other therapies, improve outcomes in HFrEF. HFpEF management focuses on comorbidity management with recent data showing benefit from SGLT-2 inhibitor, empagliflozin.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.